$955 Million is the total value of Bain Capital Life Sciences Investors, LLC's 15 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SWTX | SPRINGWORKS THERAPEUTICS INC | $305,815,000 | +55.6% | 7,281,307 | 0.0% | 32.03% | -3.7% | |
| ARQT | ARCUTIS BIOTHERAPEUTICS, INC. | $120,334,000 | +1.5% | 3,979,292 | 0.0% | 12.60% | -37.2% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $103,638,000 | +38.3% | 4,080,237 | 0.0% | 10.86% | -14.4% | |
| APTX | APTINYX INC | $23,179,000 | +93.1% | 5,558,425 | 0.0% | 2.43% | +19.6% | |
| SVRA | SAVARA INC | $22,976,000 | 0.0% | 5,128,593 | 0.0% | 2.41% | -38.1% | |
| XFOR | X4 PHARMACEUTICALS INC | $15,364,000 | -6.8% | 1,648,485 | 0.0% | 1.61% | -42.3% | |
| SLDB | SOLID BIOSCIENCES INC | $11,343,000 | +22.6% | 3,871,164 | 0.0% | 1.19% | -24.1% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, LP #2
- BC SW, LP #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.